Rallybio Statistics
Total Valuation
Rallybio has a market cap or net worth of $83.02 million. The enterprise value is $36.54 million.
| Market Cap | 83.02M |
| Enterprise Value | 36.54M |
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Rallybio has 5.30 million shares outstanding. The number of shares has increased by 1.50% in one year.
| Current Share Class | 5.30M |
| Shares Outstanding | 5.30M |
| Shares Change (YoY) | +1.50% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 18.87% |
| Owned by Institutions (%) | 33.66% |
| Float | 788,752 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 96.95 |
| Forward PS | n/a |
| PB Ratio | 1.65 |
| P/TBV Ratio | 1.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 42.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.92, with a Debt / Equity ratio of 0.00.
| Current Ratio | 12.92 |
| Quick Ratio | 11.30 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -14.98% and return on invested capital (ROIC) is -35.51%.
| Return on Equity (ROE) | -14.98% |
| Return on Assets (ROA) | -33.04% |
| Return on Invested Capital (ROIC) | -35.51% |
| Return on Capital Employed (ROCE) | -59.05% |
| Weighted Average Cost of Capital (WACC) | -0.66% |
| Revenue Per Employee | $95,333 |
| Profits Per Employee | -$868,556 |
| Employee Count | 9 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +475.47% in the last 52 weeks. The beta is -0.89, so Rallybio's price volatility has been lower than the market average.
| Beta (5Y) | -0.89 |
| 52-Week Price Change | +475.47% |
| 50-Day Moving Average | 14.70 |
| 200-Day Moving Average | 8.30 |
| Relative Strength Index (RSI) | 54.81 |
| Average Volume (20 Days) | 40,986 |
Short Selling Information
The latest short interest is 425,033, so 8.02% of the outstanding shares have been sold short.
| Short Interest | 425,033 |
| Short Previous Month | 586,906 |
| Short % of Shares Out | 8.02% |
| Short % of Float | 53.89% |
| Short Ratio (days to cover) | 5.81 |
Income Statement
In the last 12 months, Rallybio had revenue of $858,000 and -$7.82 million in losses. Loss per share was -$1.38.
| Revenue | 858,000 |
| Gross Profit | -14.68M |
| Operating Income | -29.72M |
| Pretax Income | -7.82M |
| Net Income | -7.82M |
| EBITDA | -29.66M |
| EBIT | -29.72M |
| Loss Per Share | -$1.38 |
Balance Sheet
The company has $46.80 million in cash and $154,000 in debt, with a net cash position of $46.64 million or $8.80 per share.
| Cash & Cash Equivalents | 46.80M |
| Total Debt | 154,000 |
| Net Cash | 46.64M |
| Net Cash Per Share | $8.80 |
| Equity (Book Value) | 50.28M |
| Book Value Per Share | 9.50 |
| Working Capital | 49.35M |
Cash Flow
| Operating Cash Flow | -27.59M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 67,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -27.59M |
| FCF Per Share | -$5.21 |
Margins
| Gross Margin | n/a |
| Operating Margin | -3,464.27% |
| Pretax Margin | -911.07% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Rallybio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.50% |
| Shareholder Yield | -1.50% |
| Earnings Yield | -9.40% |
| FCF Yield | -33.16% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 6, 2026. It was a reverse split with a ratio of 1:8.
| Last Split Date | Feb 6, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:8 |
Scores
Rallybio has an Altman Z-Score of -5.14 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.14 |
| Piotroski F-Score | 2 |